๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II study of Ifosfamide and Mesna in refractory adenocarcinoma of the endometrium

โœ Scribed by Gregory P. Sutton; John A. Blessing; Howard D. Homesley; William P. McGuire; Leon Adcock

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
308 KB
Volume
73
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A Phase II study of paclitaxel and ifosf
A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium
โœ Christopher J. Sweeney; Stephen D. Williams; David E. Finch; Richard Bihrle; Ric ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 62 KB ๐Ÿ‘ 2 views

## BACKGROUND. Cisplatin-based combination chemotherapy for patients with advanced transitional cell carcinoma (TCC) of the urothelium has limitations, and new therapies need to be evaluated. METHODS. Ifosfamide 1.0 gm/m 2 on Days 1-4 and paclitaxel 135 mg/m 2 by 24-hour infusion on Day 4 were ad

Phase II trial of ifosfamide and mesna i
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8552
โœ Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 481 KB

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and